Beamtree Holdings Limited (ASX:BMT) Announces 1H FY25 Results
Beamtree Holdings Limited (ASX:BMT) reports a 10% revenue increase in 1H FY25 and launches its Integrated Coding Platform in Saudi Arabia.
Category: Healthcare
Imagion Biosystems (ASX:IBX) Starts Manufacturing for Phase 2 HER2+ Breast Cancer Study
Imagion Biosystems (ASX:IBX) commences manufacturing of MagSense® for its Phase 2 HER2+ breast cancer clinical study, advancing its cancer diagnostic platform.
Neuren Pharmaceuticals (ASX:NEU) Receives FDA Fast Track for NNZ-2591 in Pitt Hopkins Syndrome
Neuren Pharmaceuticals (ASX:NEU) gains FDA Fast Track designation for NNZ-2591 to treat Pitt Hopkins syndrome, following successful Phase 2 trial.
IDT Australia Limited (ASX:IDT) Announces Half-Year Financial Results
IDT Australia Limited (ASX:IDT) reports an 83% revenue increase and a 15.8% reduction in loss for the half-year ended December 2024.
Optiscan Imaging Ltd (ASX:OIL) Launches InForm™ Imaging Device for Pathology
Optiscan Imaging Ltd (ASX:OIL) launches InForm™, a groundbreaking pathology imaging device enhancing diagnostic workflows and accuracy.
Pharmx Technologies Limited (ASX:PHX) Announces H1 FY25 Results
Pharmx Technologies Limited (ASX:PHX) reports a 17% revenue increase in H1 FY25, driven by strategic growth and partnerships.
Nyrada Inc. (ASX:NYR) Reports Half-Year Financial Results
Nyrada Inc. (ASX:NYR) reports a 64% revenue decline and a $2.46m loss for the half-year, while advancing its leading drug candidate to clinical trials.
Zelira Therapeutics (ASX:ZLD) Secures $1.15M R&D Tax Refund
Zelira Therapeutics (ASX:ZLD) secures a $1.15M refund under the R&D Tax Incentive Scheme to advance clinical programs and business operations.
Opthea Limited (ASX:OPT) Completes Final Patient Visit in Phase 3 COAST Trial
Opthea (ASX:OPT) completes final patient visit in COAST Phase 3 trial, anticipating topline results in early Q2 CY25.
Biome Australia Limited (ASX:BIO) Reports First Net Profit and Unveils Vision 27 Strategic Plan
Biome Australia (ASX:BIO) reports its first net profit in H1 FY25 and launches Vision 27 strategic plan with $75-$85m revenue guidance.